Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma (NCT07324629) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
China30 participantsStarted 2026-06
Plain-language summary
The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are:
* How effective is drug Sac-TMT in treating Thymic Carcinoma?
* What adverse events (AEs) do participants have when taking drug Sac-TMT?
Participants will:
* Progress after at least one platinum-based chemotherapy treatment.
* Take drug Sac-TMT every 2 weeks.
* Take tumor response assessments every 6 weeks.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Males or females aged ≥ 18 to ≤ 75 years at the time of signing the Informed Consent Form;
* Participants with histologically or cytologically confirmed thymic carcinoma, and locally advanced or metastatic thymic carcinoma who are not suitable for curative intent therapy;
* Participants with advanced thymic carcinoma who have progressed after at least one prior platinum-based chemotherapy;
* Able to provide a tumor tissue sample at the time of or after the diagnosis of locally advanced or metastatic tumor;
* At least one measurable target lesion that has not received radiotherapy according to RECIST v1.1;
* ECOG performance status score of 0 or 1;
* Expected survival ≥ 12 weeks;
* Adequate organ and bone marrow function.
Exclusion Criteria:
* Participants with histologically or cytologically confirmed thymoma or thymic neuroendocrine tumor;
* Participants with known metastases to meninges, brainstem metastases, spinal cord metastases and/or compression, active or untreated brain metastases;
* Participants with other malignant tumors within 3 years prior to the first dose;
* Presence of any of conditions or risk factors related to cardiovascular and cerebrovascular diseases;
* Uncontrolled systemic disease as judged by the investigator;
* History of interstitial lung disease/noninfectious pneumonitis requiring steroid therapy;
* Clinically severe pulmonary impairment due to lung disorder;
* Presence of active hepatitis B or hepatitis C;
* Known active …
What they're measuring
1
ORR
Timeframe: From enrollment to the end of treatment at 24 months